# Effect of Benralizumab in Atopic Dermatitis

> **NCT03563066** · PHASE2 · COMPLETED · sponsor: **McMaster University** · enrollment: 20 (actual)

## Conditions studied

- Dermatitis, Atopic
- Dermatitis
- Eczema
- Skin Diseases
- Skin Diseases, Genetic
- Genetic Diseases, Inborn
- Skin Diseases, Eczematous
- Hypersensitivity
- Hypersensitivity, Immediate
- Immune System Diseases

## Interventions

- **DRUG:** Benralizumab
- **DRUG:** Placebo Control

## Key facts

- **NCT ID:** NCT03563066
- **Lead sponsor:** McMaster University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-04
- **Primary completion:** 2021-09-28
- **Final completion:** 2021-09-28
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03563066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03563066, "Effect of Benralizumab in Atopic Dermatitis". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03563066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*